Merck's (MRK) Keytruda Steals the Show at ESMO - Leerink

October 10, 2016 7:59 AM EDT
Get Alerts MRK Hot Sheet
Price: $60.28 --0%

Rating Summary:
    13 Buy, 10 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 19 | New: 15
Trade MRK Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Leerink Partners analyst Seamus Fernandez weighed in on Merck (NYSE: MRK) after Keytruda steals the show at ESMO.

Fernandezcommented, "Benefits of Keytruda in Keynote-024 support MRK's view that a “sea change” in treatment in patients with PDL1 >50% is imminent. The nearly inexplicable failure of BMY (OP) CM-026 at every level of PDL1 expression and confusion over imbalances in CM-026 puts MRK in the driver's seat in 1L lung cancer for at least the next 12-18 months, but given the stunning 50% reduction in the risk of progression or death (p=<0.001; 95% confidence interval, 0.37–0.68) together with a 40% reduction in the risk of death (p=0.005; 95% CI, 0.41–0.89), we fully expect MRK to retain a significant place at the table long term. We note that median overall survival for Keytruda of 10.3 months (95% CI, 6.7 to not reached) is consistent with our modeling assumptions. In addition, confirmation that Keytruda is clearly benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility that MRK could compete broadly in the overall non-squamous patient population."

The firm maintained an Market Perform rating and price target of $65 on MRK.

For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.

Shares of Merck closed at $62.77 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Add Your Comment